The European Commission has granted the amyloid-beta monoclonal antibody Leqembi Marketing Authorization in the European Union. Lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to AD who are apolipoprotein E 4 non-carriers or heterozygotes with confirmed amyloid pathology, Biogen (BIIB) announced. “Eisai (ESAIY) and Biogen will issue a full press release on the approval this evening,” the company added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Eisai, Biogen announce update on regulatory review of MAA for lecanemab
- Biogen price target lowered to $165 from $168 at Guggenheim
- Morning Movers: Pharmaceuticals sink as impending tariffs seen coming
- Biogen price target lowered to $152 from $157 at Morgan Stanley
- Biogen cut to Hold at Argus on expected earnings decline